RT Journal Article SR Electronic T1 MDR-TB treatment outcomes in HIV positive patients JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP P3056 VO 44 IS Suppl 58 A1 Alena Skrahina A1 Andrei Khaliaukin A1 Henadz Hurevich A1 Liudmila Zhylevich A1 Valiantsin Rusovich A1 Evgeni Belilovski A1 Aliaksandr Shyrayeu A1 Masoud Dara YR 2014 UL http://erj.ersjournals.com/content/44/Suppl_58/P3056.abstract AB Observational data from MDR-TB high burden countries on the outcome of MDR-TB in HIV positive populations remain sparse. In terms of MDR-TB and HIV TB co-infection Gomel region (1.5 million populations) is the most problematic region in Belarus.The aim of the study was to compare treatment outcomes of patients who were diagnosed with HIV and MDR-TB in Gomel region of Belarus to HIV positive patients whose M.tb isolates were susceptible to isoniazid (H) and rifampicin (R).Between 01.01.2010 and 31.12.2011 327 HIV positive individuals with TB and available drug susceptibility testing results were included in the study. MDR-TB was laboratory confirmed in 86 patients, H and R susceptible TB (S-TB) was diagnosed in 241 patientsProportion of successfully treated HIV positive patients with S-TB was higher but not significantly in compared to those with MDR-TB: 36% vs. 27% (OR=0.65; 95% CI 0.37-1.11; p>0.05). Treatment failure was recorded approximately in the same proportion of both groups of HIV/TB patients: 30% vs. 28% (OR=1.14; 95% CI 0.66-1.97; p>0.05). Statistically significant difference between the groups was observed only in death rate: 31% vs. 44% (OR=0.57; 95% CI 0.34-0.95; p<0.05)In these first HIV/TB patients placed on WHO recommended tretment, diagnostics were not optimized with use of rapid molecular tests, regimens were characterized with negligible access to later-generation fluoroquinolones and to early start of antiretrovirals. Many patients had long-standing disease and more extensive lesions. No social support was provided to patients before 2011. With rapid diagnostics, enhanced MDR-TB regimens, expanded provision of antiretrovirals and social support to patients treatment outcomes are expected to improve.